Stevens-Johnson syndrome and toxic epidermal necrolysis: What do we know?

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 669-672

  Tartarone, Alfredo ^a   Lerose, Rosa ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

drug interaction; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; MACROLIDE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

CRITICALLY ILL PATIENT; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNE RESPONSE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RARE DISEASE; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

CRITICAL ILLNESS; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; PHARMACEUTICAL PREPARATIONS; STEVENS-JOHNSON SYNDROME;

EID: 78650259565     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f2f24f     Document Type: Review

References (34)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
3. Letko E, Papaliodis DN, Papaliodis GN et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94:419-435.
4. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Jones syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol. 2008;128:35-44.
5. Devi K, George S, Criton S, et al. Carbamazepine, the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian Dermatol Venereol Leprol. 2005;71:325-328.
6. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on severe cutaneous adverse reactions. Lancet. 1999;353:2190-2194.
7. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.
8. Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatology Therapy. 2009;22:441-451.
9. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60-68.
10. Horne NS, Narayan AR, Young RM, et al. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5:160-164.
11. Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26:567-574.
12. Borchers AT, Lee JL, Naguwa SM, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmunity Reviews. 2008;7:598-605.
13. Nagy N, McGrath JA. Blistering skin disease: a bridge between dermatopathology and molecular biology. Histopathology. 2010;56:91-99.
14. Weltzien HU, Marlon C, Martin S, et al. T cell immune response to haptens: structural models for allergic and autoimmune reactions. Toxicology. 1996;107:141-151.
15. Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considerations, pathobiology and targeted treatments revisited. Drug Saf. 2010;33:189-212.
16. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptor: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2:301-305.
17. Paquet P, Pierard GE. Glutathione-S-transferase p expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratino-cytes. Skin Pharmacol Physiol. 2007;20:66-70.
18. Hayes J, Pulford D. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600.
19. Lissia M, Mulas P, Bulla A, et al. Toxic epidermial necrolysis (Lyell's disease). Burns. 2010;36:152-163.
20. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 2007;25:348-349.
21. Wolf R, Wolf D, Davidovici B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol. 2007;25:348-349.
22. Lamoreux MR, Sternbach MR. Erythema multiforme. Am Fam Physician. 2006;74:1883-1888.
23. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study in patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.
24. Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J. 2008;84:60-65.
25. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
26. Paquet P, Jacob E, Damas P, et al. Treatment of drug-induced toxic epidermal necrolysis (Lyell syndrome) with intravenous human immu-noglobulins. Burns. 2001;27:652-655.
27. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46:1092-1094.
28. Chave TA, Mortimer MJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153:241-253.
29. Herndon D. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg. 1995;180:340-342.
30. Kelemen JJ, Cioffi W, McManus W, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg. 1995;180:283-288.
31. Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroids in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48:1122-1128.
32. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998; 352:1586-1589.
33. Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J Med. 2009;361:1088-1097.
34. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115: 149-153.